|
|
|
|
|
Effects of Huaxian capsule Ⅱ on PCT,WBC and CRP in patients with sepsis due to Qi deficiency and blood stasis syndrome |
Liang Qun, Zhang Tian-yu, Zhu Yong-zhi, Xie Li-xiang, Sun De-yang, Yang Yang |
Department of Critical Care Medicine, the First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150040, China |
|
|
Abstract Objective To investigate the effects of Huaxian capsule Ⅱ on procalcitonin (PCT), white blood cell count (WBC) and C-reactive protein (CRP) in patients with sepsis due to Qi deficiency and blood stasis syndrome. Methods Sixty cases of patients with sepsis and the TCM symptom type with Qi deficiency and blood stasis syndrome from January 2015 to December 2016 in our hospital ICU ward were randomly divided into two groups according to randomized controlled trials, namely the experimental group and the control group. The control group was given symptomatic treatment according to the conventional treatment of sepsis. The experimental group was treated with the Huaxian capsule Ⅱ water decoction on the basis of the treatment of the control group. Two groups of patients received peripheral vein blood sampling after 7 days, and the influence of Huaxian capsule Ⅱ on PCT, WBC and CRP were observed in patients with Qi deficiency and blood stasis type of sepsis. Results After treatment, PCT in the experimental group decreased from (4.27±0.56) μg/L to (1.17±0.25) μg/L, WBC from (20.19±2.63)×109/L to (12.09±1.97)×109/L, CRP from (269.25±81.31 ) mg/L to (14.18±7.43) mg/L, and APACHEⅡ score from (29.23±2.91) to (19.87±2.03). The decrease of PCT, WBC, CRP and APACHEⅡ scores was significantly greater than that of the control group ( P < 0.05). Conclusion Huaxian capsule Ⅱ can reduce the levels of PCT, WBC, CRP, APACHE Ⅱ score in patients with sepsis, and alleviate the further development of sepsis.
|
|
Corresponding Authors:
Zhang Tian-yu, E-mail: 2717912004@qq.com
|
|
|
|
[1]Dellinger RP, Levy MM, Rhodes A,et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and 〖JP2〗septic shock: 2012[J]. Intensive Care Med, 2013, 39(2): 165-228.[2]van der Poll T, van de Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets[J]. Nat Rev Immunol, 2017, 17 (7):407-420.[3]Qun L, Han L, Tianyu Z, et al. Potential urine biomarkers from a high throughput metabolomics study of severe sepsis in a large Asian cohort[J]. Rsc Advances, 2015, 5(124):102 204-102 209.[4]赵国桢,郭玉红,李博,等. 中医药防治脓毒症的研究进展[J]. 中国中药杂志, 2017, 42 (8):1423-1429.[5]闰圣涛,李红伟,张国虹,等. 脓毒症发病机制及标志物新进展[J]. 中日友好医院学报, 2014, 28(6): 355-357.[6]李钢,赵金锋,王凯诚,等. 参附注射液对试验性脓毒症大鼠部分神经内分泌免疫因子的影响[J]. 中国中西医结合外科杂志, 2011, 17(2):185-189.[7]中华医学会重症医学分会. 中国严重脓毒症/感染性休克治疗指南(2014)[J]. 全科医学临床与教育, 2015, 54(4):365-367.[8]中华医学会急诊医学分会危重病专家委员会, 中国中西医结合学会急救医学专业委员会. 脓毒症的定义、诊断标准、中医证候诊断要点及说明(草案)[J]. 中华急诊医学杂志, 2007, 16(8):797-798.[9]张野.血必净治疗脓毒症(气虚血瘀型)的临床疗效观察[D]. 哈尔滨: 黑龙江中医药大学, 2015.[10]王林, 罗苑苑, 陶如,等. 黄连解毒汤加减治疗热毒型脓毒症临床研究[J]. 中医学报, 2017, 32(8):1527-1530.[11]李皖生, 徐道剑, 王国涛. 参麦注射液治疗脓毒症临床效果及对LAC、NSE和S100B蛋白的影响[J]. 中华中医药学刊, 2018, 36(3): 688-691.[12]张晓忠, 杨广, 李健. 参麦注射液对脓毒症临床指标影响的Meta分析[J]. 中国中医急症, 2017, 26(11): 1903-1906.[13]Mira JC, Gentile LF, Mathias BJ,et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome[J]. Crit Care Med, 2017, 45 (2):253-262.[14]Li C, Wang P, Zhang L, et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials[J]. J Ethnopharmacol, 2018, 224:512-521.[15]肖莹莹,周仙仕,唐光华.脓毒症患者中医证候与预后的关系[J]. 中医杂志, 2016, 57 (3):224-227.[16]赵昕,蓝海涛,王颖辉,等. 脓毒症中医证型证素分布与炎症指标及预后的关系研究[J]. 北京中医药, 2017(1):13-17.[17]辛显波,崔磊. 中药雾化吸入联合保留灌肠治疗脓毒症临床研究[J]. 中医临床研究, 2018, 10(11):113-114.[18]Liang Q, Lin H, Xing H, et al. Urinary UPLC-MS metabolomics dissectiog the underlying mechanisms of huaxian capsule protects against sepsis[J]. RSC Adv, 2016: 10.1039. C6RA07987C.[19]Cui N,Zhang H,Chen Z,et al. Prognostic significance of PCT and CRP evaluation for adult ICU patients with sepsis and septic shock: retrospective analysis of 59 cases[J]. J Int Med Res, 2019, 47(4):1573-1573.[20]周勇,陈大庆,李萌芳,等.脓毒血症患者血清白细胞介素-27和C-反应蛋白及降钙素原水平与病情严重程度的关系研究[J].中华医院感染学杂志, 2017, 27(24):5546-5548, 5553.[21]邵文霞. 败血症患儿体内T细胞亚群及鉴别诊断指标IL-6、CRP和PCT的研究[D].浙江大学, 2018.[22]Kumar Jogender,Singh Amitabh. A Comparative Evaluation of Presepsin with Procalcitonin and CRP in Diagnosing Neonatal Sepsis: Correspondence.[J]. Indian journal of pediatrics, 2018.[23]Dong J Z, Wang L P, Zhu J H. Appropriate Antibiotic Therapy and WBC in Sepsis: Factors to Consider.[J]. Critical Care Medicine, 2016, 44(4):e231.[24]宗慧丽. 联合NGAL、PCT、BNP、乳酸和APACHE Ⅱ评分在脓毒症患者中的相关性研究[D].郑州大学, 2017. |
|
|
|